G-CSF for clinical use is mainly indicated to reduce neutropenia duration and fevered neutropenia incidence in patients with non-myelogenic neoplasia, undergoing cytotoxic chemotherapy. This evidence concerns the gene CSF3 and Decreased total neutrophil count.